The DOI matches its Crossref record; 482 of the 482 references it cites were found in a registry or an index.
The multi-factorial nature of clinical multidrug resistance in cancer
Abstract
Curative cancer therapy remains a major challenge particularly in cancers displaying multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a wide array of anticancer drugs harboring distinct structures and mechanisms of action. The multiple factors involved in mediating MDR may include host factors, tumor factors as well as tumor-host interactions. Among the host factors are genetic variants and drug-drug interactions. The plethora of tumor factors involves decreased drug uptake primarily via impaired influx transporters, increased drug efflux predominantly due to the overexpression of MDR efflux transporters of the ATP-binding cassette superfamily or due to drug efflux mediated by extracellular vesicles (EVs) or drug-loaded lysosomes undergoing exocytosis, deregulation of cell death mechanisms (i.e. anti-apoptotic modalities), enhanced DNA damage repair, epigenetic alterations and/or deregulation of microRNAs. The intratumor heterogeneity and dynamics, along with cancer stem cell plasticity, are important tumor factors. Among the tumor-host interactions are the role of the tumor microenvironment, selective pressure of various stressor conditions and agents, acidic pH and the intracellular transfer of traits mediated by EVs. The involvement of these diverse factors in MDR, highlights the need for precision medicine and real-time personalized treatments of individual cancer patients. In this review, written by a group of researchers from COST Action STRATAGEM "New diagnostic and therapeutic tools against multidrug resistant tumors", we aim to bring together these multidisciplinary and interdisciplinary features of MDR cancers. Importantly, it is becoming increasingly clear that deciphering the molecular mechanisms underlying anticancer drug resistance, will pave the way towards the development of novel precision medicine treatment modalities that are able to surmount distinct and well-defined mechanisms of anticancer drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–400 of 482
Tang, J., Wang, F., Cheng, G., Si, S., Sun, X., Han, J., Yu, H., Zhang, W., Lv, Q., Wei, J.-F., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0706-6 · Cited by 178
Feng, D., Zhang, H., Zhang, P., Zheng, Y., Zhang, X., Han, B., Luo, X., Xu, L., Zhou, H., Qu, L., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01213.x · Cited by 175
Hocine, H. R., Costa, H. E., Dam, N., Giustiniani, J., Palacios, I., Loiseau, P., Bensussan, A., Borlado, L. R., Charron, D., Suberbielle, C., et al. (2017) · Scientific Reports · doi:10.1038/srep44720 · Cited by 175
Breast-cancer stem cells—beyond semantics
Badve, S., & Nakshatri, H. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70191-7 · Cited by 174
Teo, Y. L., Ho, H. K., & Chan, A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12496 · Cited by 171
Chen, J., Ding, Z., Peng, Y., Pan, F., Li, J., Zou, L., Zhang, Y., & Liang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098882 · Cited by 170
miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
Sun, C., Li, N., Yang, Z., Zhou, B., He, Y., Weng, D., Fang, Y., Wu, P., Chen, P., Yang, X., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt302 · Cited by 169
Glucosylceramide: a marker for multiple-drug resistant cancers.
Lucci, A., Cho, W. I., Han, T., Giuliano, A. E., Morton, D. L., & Cabot, M. C. (1998) · PubMed · Cited by 168
Li, H.-Y., Liang, J.-L., Kuo, Y.-L., Lee, H.-H., Calkins, M. J., Chang, H.-T., Lin, F.-C., Chen, Y.-C., Hsu, T.-I., Hsiao, M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0918-2 · Cited by 168
Romidepsin: a novel histone deacetylase inhibitor for cancer
Bertino, E. M., & Otterson, G. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594437 · Cited by 166
Qiao, Y., Zhang, C., Li, A., Wang, D., Luo, Z., Ping, Y., Zhou, B., Liu, S., Li, H., Yue, D., et al. (2018) · Oncogene · doi:10.1038/onc.2017.387 · Cited by 166
Heymach, J. V., Krilov, L., Alberg, A. J., Baxter, N. N., Chang, S. M., Corcoran, R. B., Dale, W., DeMichele, A. M., Diefenbach, C., Dreicer, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0446 · Cited by 166
Tamm, I., Richter, S., Oltersdorf, D., Creutzig, U., Harbott, J., Scholz, F., Karawajew, L., Ludwig, W.-D., & Wuchter, C. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0642 · Cited by 165
To, K. K. W., Zhan, Z., Litman, T., & Bates, S. E. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00331-08 · Cited by 164
Dezentjé, V. O., van Blijderveen, N. J. C., Gelderblom, H., Putter, H., van Herk-Sukel, M. P. P., Casparie, M. K., Egberts, A. C. G., Nortier, J. W. R., & Guchelaar, H.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0894 · Cited by 163
Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
Zhitomirsky, B., & Assaraf, Y. G. (2017) · Oncotarget · doi:10.18632/oncotarget.15155 · Cited by 163
Self-citationUsanova, S., Piée-Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 162
Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles
Sousa, D., Lima, R. T., & Vasconcelos, M. H. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.08.002 · Cited by 162
Self-citationBruhn, O., & Cascorbi, I. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.952630 · Cited by 161
Meeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 161
van der Veldt, A. A. M., Eechoute, K., Gelderblom, H. A. J., Gietema, J. A., Guchelaar, H., van Erp, N. P., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Mathijssen, R. H. J., & Wessels, J. A. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1828 · Cited by 160
Boyerinas, B., Park, S., Murmann, A. E., Gwin, K., Montag, A. G., Zillhardt, M., Hua, Y., Lengyel, E., & Peter, M. E. (2012) · International Journal of Cancer · doi:10.1002/ijc.26190 · Cited by 159
Borel, F., Han, R., Visser, A., Petry, H., van Deventer, S. J. H., Jansen, P. L. M., & Konstantinova, P. S. (2011) · Hepatology · doi:10.1002/hep.24682 · Cited by 157
Gottesman, M. M., & Pastan, I. H. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv222 · Cited by 153
Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia
Wong, K. K., Lawrie, C. H., & Green, T. (2019) · Biomarker Insights · doi:10.1177/1177271919846454 · Cited by 153
Kharaziha, P., Chioureas, D., Rutishauser, D., Baltatzis, G., Lennartsson, L., Fonseca, P., Azimi, A., Hultenby, K. R., Zubarev, R. A., Ullén, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3226 · Cited by 152
Resistance to Cell Death and Its Modulation in Cancer Stem Cells
Safa, A. R. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2016016976 · Cited by 152
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00452-4 · Cited by 151
Yu, T., Yang, G., Hou, Y., Tang, X., Wu, C., Wu, X.-A., Guo, L., Zhu, Q., Luo, H., Du, Y.-E., et al. (2016) · Oncogene · doi:10.1038/onc.2016.370 · Cited by 151
Variability in bioavailability of small molecular tyrosine kinase inhibitors
Herbrink, M., Nuijen, B., Schellens, J. H. M., & Beijnen, J. H. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.005 · Cited by 149
Epigenetic regulation of gene expression in cancer: techniques, resources and analysis
Kagohara, L. T., Stein-O’Brien, G., Kelley, D. Z., Flam, E. L., Wick, H. C., Danilova, L., Easwaran, H., Favorov, A. V., Qian, J. X., Gaykalova, D. A., et al. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx018 · Cited by 149
Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer
Chen, J., Tian, W., Cai, H., He, H., & Deng, Y. (2011) · Medical Oncology · doi:10.1007/s12032-011-0117-4 · Cited by 147
Multi-Organs-on-Chips: Towards Long-Term Biomedical Investigations
Zhao, Y., Kankala, R. K., Wang, S., & Chen, A. (2019) · Molecules · doi:10.3390/molecules24040675 · Cited by 147
Manipulating tumor acidification as a cancer treatment strategy.
McCarty, M. F., & Whitaker, J. (2010) · PubMed · Cited by 145
Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions
van Leeuwen, R. W. F., Jansman, F. G. A., van den Bemt, P. M. L. A., de Man, F. M., Piran, F., Vincenten, I., Jager, A., Rijneveld, A. W., Brugma, J.-D. C., Mathijssen, R. H. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv029 · Cited by 145
Shen, J., Yin, Q., Chen, L., Zhang, Z., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.007 · Cited by 143
Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic
Lobo, J., Gillis, A., Jerónimo, C., Henrique, R., & Looijenga, L. H. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020258 · Cited by 143
Kruh, G. D., Guo, Y., Hopper-Borge, E. A., Belinsky, M. G., & Chen, Z. (2006) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0114-1 · Cited by 142
Microenvironment-derived factors driving metastatic plasticity in melanoma
Kim, I. S., Heilmann, S., Kansler, E. R., Zhang, Y., Zimmer, M. A., Ratnakumar, K., Bowman, R. L., Simon-Vermot, T., Fennell, M., Garippa, R. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14343 · Cited by 142
Jain, P. G., & Patel, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.024 · Cited by 142
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 141
Dl, Y., Bb, S., Liu, J., Wenyu, W., & Shu, Y.-Q. (2017) · PubMed · Cited by 141
Extracellular acidity and increased exosome release as key phenotypes of malignant tumors
Logozzi, M., Spugnini, E. P., Mizzoni, D., Raimo, R. D., & Fais, S. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09783-8 · Cited by 140
Cancer Stem Cells: From Historical Roots to a New Perspective
Capp, J. (2019) · Journal of Oncology · doi:10.1155/2019/5189232 · Cited by 140
Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer
Yang, S., Wang, D., Li, J., Xu, H., Shen, H.-Y., Chen, X., Zhou, S., Zhong, S., Zhao, J., & Tang, J. (2017) · Gene · doi:10.1016/j.gene.2017.04.031 · Cited by 139
Rodríguez‐Antona, C., Gomez, A. V., Karlgren, M., Sim, S. C., & Ingelman‐Sundberg, M. (2009) · Human Genetics · doi:10.1007/s00439-009-0748-0 · Cited by 138
Coronel, J., Cetina, L., Pacheco‐Bravo, I., Trejo‐Becerril, C., González‐Fierro, A., la Cruz-Hernández, E. N. D., Pérez‐Cárdenas, E., Taja‐Chayeb, L., Arias-Bofill, D., Candelaria, M., et al. (2010) · Medical Oncology · doi:10.1007/s12032-010-9700-3 · Cited by 138
Fu, X.-T., Song, K., Zhou, J., Shi, Y.-H., Liu, W.-R., Shi, G., Gao, Q., Wang, X.-Y., Ding, Z.-B., & Fan, J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0771-8 · Cited by 137
Targeting Autophagy to Overcome Drug Resistance in Cancer Therapy
Kumar, A., Singh, U. K., & Chaudhary, A. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.88 · Cited by 136
Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method
van Leeuwen, R. W. F., Swart, E. L., Boven, E., Boom, F. A., Schuitenmaker, M. G., & Hugtenburg, J. G. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq761 · Cited by 135
Ceccaldi, R., O’Connor, K. W., Mouw, K. W., Li, A. Y., Matulonis, U. A., D’Andrea, A. D., & Konstantinopoulos, P. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2593 · Cited by 133
Sträter, J., Hinz, U., Walczak, H., Mechtersheimer, G., Koretz, K., Herfarth, C. H., Möller, P., & Lehnert, T. (2002) · PubMed · Cited by 131
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis
Mizutani, Y., Nakanishi, H., Li, Y. Z., Matsubara, H., Yamamoto, K., Sato, N., Shiraishi, T., Nakamura, T., Mikami, K., Okihara, K., et al. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.919 · Cited by 129
Xiao, F.-M., Bai, Y., Chen, Z., Li, Y., Luo, L., Huang, J., Yang, J., Liao, H., & Guo, L. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.024 · Cited by 127
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples
Martelotto, L. G., Baslan, T., Kendall, J., Geyer, F. C., Burke, K. A., Spraggon, L., Piscuoglio, S., Chadalavada, K., Nanjangud, G. J., Ng, C. K. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4279 · Cited by 127
Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
Anreddy, N., Gupta, P., Kathawala, R. J., Patel, A. S., Wurpel, J. N. D., & Chen, Z. (2014) · Molecules · doi:10.3390/molecules190913848 · Cited by 126
Role of PARP Inhibitors in Cancer Biology and Therapy
Davar, D., Beumer, J. H., Hamieh, L., & Tawbi, H. A.-H. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802002464 · Cited by 126
Han, B. W., Feng, D., Li, Z., Luo, X.-Q., Zhang, H., Li, X.-J., Zhang, X.-J., Zheng, L.-L., Zeng, C.-W., Lin, K.-Y., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr428 · Cited by 126
Zhitomirsky, B., Yunaev, A., Kreiserman, R., Kaplan, A., Stark, M., & Assaraf, Y. G. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1227-0 · Cited by 126
Self-citationDaigo, S., Takahashi, Y., Fujieda, M., Ariyoshi, N., Yamazaki, H., Koizumi, W., Tanabe, S., Saigenji, K., Nagayama, S., Ikeda, K., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00005 · Cited by 125
Role of copper transporters in platinum resistance
Kilari, D. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.106 · Cited by 124
UCH‐L1‐containing exosomes mediate chemotherapeutic resistance transfer in breast cancer
Ning, K., Wang, T., Sun, X., Zhang, P., Chen, Y., Jin, J., & Hua, D. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24614 · Cited by 123
Blagitko‐Dorfs, N., Schlosser, P., Greve, G., Pfeifer, D., Meier, R., Baude, A., Brocks, D., Plass, C., & Lübbert, M. (2018) · Leukemia · doi:10.1038/s41375-018-0293-8 · Cited by 122
van Leeuwen, R. W. F., Peric, R., Hussaarts, K. G. A. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2560 · Cited by 121
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Ng, C. K. Y., Bidard, F., Piscuoglio, S., Geyer, F. C., Lim, R. S., de Bruijn, I., Shen, R., Pareja, F. G., Berman, S., Wang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3115 · Cited by 121
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Jaramillo, A. C., Saig, F. A., Cloos, J. J., Jansen, G., & Peters, G. J. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.02 · Cited by 120
Kato, T., Mizutani, K., Kameyama, K., Kawakami, K., Fujita, Y., Nakane, K., Kanimoto, Y., Ehara, H., Ito, H., Seishima, M., et al. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.04.019 · Cited by 117
Ion channels and transporters in the development of drug resistance in cancer cells
Hoffmann, E. K., & Lambert, I. H. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0109 · Cited by 116
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 116
Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., Wang, X., Liu, Y., Xu, N., Yan, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3563 · Cited by 113
DNA methylation and histone modifications as epigenetic regulation in prostate cancer
Nowacka‐Zawisza, M., & Wiśnik, E. (2017) · Oncology Reports · doi:10.3892/or.2017.5972 · Cited by 113
The emerging roles of macrophages in cancer metastasis and response to chemotherapy
Sanchez, L. R., Borriello, L., Entenberg, D. R., Condeelis, J. S., Oktay, M. H., & Karagiannis, G. S. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0218-056rr · Cited by 113
Sullivan, R., Maresh, G., Zhang, X., Salomon, C., Hooper, J., Margolin, D., & Li, L. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00194 · Cited by 112
Chou, C.-W., Wang, C.-C., Wu, C., Lin, Y., Lee, Y.-C., Cheng, Y.-W., & Hsieh, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos195 · Cited by 111
Zhang, L., Pan, L., Xiang, B., Zhu, H., Wu, Y., Chen, M., Guan, P., Zou, X., Valencia, C. A., Dong, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9021 · Cited by 111
DNMT Inhibitors Increase Methylation in the Cancer Genome
Giri, A. K., & Aittokallio, T. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00385 · Cited by 111
Chu, M. P., Ghosh, S., Chambers, C. R., Basappa, N. S., Butts, C. A., Chu, Q. S.-C., Fenton, D. W., Joy, A. A., Sangha, R. S., Smylie, M., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.07.005 · Cited by 108
Ferreira, C. G., van der Valk, P., Span, S. W., Jonker, J. M., Postmus, P. E., Kruyt, F. A. E., & Giaccone, G. (2001) · Annals of Oncology · doi:10.1023/a:1011167113067 · Cited by 107
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer
Chu, M. P., Hecht, J. R., Slamon, D. J., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3358 · Cited by 107
CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway
Wang, L., Zhang, F., Cui, J., Chen, L., Chen, Y., & Liu, B. (2018) · Oncology Reports · doi:10.3892/or.2018.6311 · Cited by 106
Sharma, M., Holmes, H. M., Mehta, H. B., Chen, H., Aparasu, R. R., Shih, Y. T., Giordano, S. H., & Johnson, M. L. (2019) · Cancer · doi:10.1002/cncr.31917 · Cited by 106
Adar, Y., Stark, M., Bram, E. E., Nowak-Sliwinska, P. M., van den Bergh, H., Szewczyk, G. M., Sarna, T., Składanowski, A., Griffioen, A. W., & Assaraf, Y. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.30 · Cited by 105
Self-citationEpigenetic biomarkers in urological tumors: A systematic review
Jerónimo, C., & Henrique, R. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.12.026 · Cited by 104
Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance
Goler-Baron, V., & Assaraf, Y. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016007 · Cited by 104
Self-citationAdvances in liquid biopsy approaches for early detection and monitoring of cancer
Babayan, A., & Pantel, K. (2018) · Genome Medicine · doi:10.1186/s13073-018-0533-6 · Cited by 104
Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors
Rye, I. H., Trinh, A. C., Sætersdal, A. B., Nebdal, D. J. H., Lingjærde, O. C., Almendro, V., Polyák, K., Børresen‐Dale, A., Helland, Å., Markowetz, F. M., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12375 · Cited by 103
Perez, E. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0005-6 · Cited by 101
Duvvuri, M., Gong, Y., Chatterji, D., & Krise, J. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400735200 · Cited by 101
Qin, Y., Zhang, S., Deng, S., An, G. C., Qin, X., Li, F., Xu, Y., Hao, M., Yang, Y., Zhou, W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.325 · Cited by 101
Clinically relevant drug interactions with multikinase inhibitors: a review
Hussaarts, K. G. A. M., Veerman, G., Jansman, F. G. A., van Gelder, T., Mathijssen, R. H. J., & van Leeuwen, R. W. F. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818347 · Cited by 101
Mechanisms of Resistance to Cabazitaxel
Durán, G. E., Wang, Y. C., Francisco, E. B., Rose, J. C., Martinez, F. J., Coller, J., Brassard, D., Vrignaud, P., & Sikic, B. I. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0155 · Cited by 100
Role of the Drug Transporter ABCC3 in Breast Cancer Chemoresistance
Andugulapati, S. B., Udupa, N., Chamallamudi, M. R., Gupta, V., & Rangarajan, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155013 · Cited by 100
To, K. K. W., Leung, W. W., & Ng, S. S. M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.09.011 · Cited by 99
Lesniak, D. M., Xu, Y., Deschênes, J., Lai, R. L., Thoms, J., Murray, D., Gosh, S., Mackey, J. R., Sabri, S., & Abdulkarim, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1591 · Cited by 99
Epigenetic biomarkers in epithelial ovarian cancer
Gloss, B., & Samimi, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.036 · Cited by 97
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 97
Personalized medicine—a modern approach for the diagnosis and management of hypertension
Savoia, C., Volpe, M., Grassi, G., Borghi, C., Rosei, E. A., & Touyz, R. M. (2017) · Clinical Science · doi:10.1042/cs20160407 · Cited by 97
Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance
Najafi, M., Mortezaee, K., & Ahadi, R. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.076 · Cited by 97
New Insights into the Epigenetics of Hepatocellular Carcinoma
Wahid, B., Ali, A., Rafique, S., & Idrees, M. (2017) · BioMed Research International · doi:10.1155/2017/1609575 · Cited by 96
Li, Y., Yin, J., Liu, Z., & Li, X. (2018) · IUBMB Life · doi:10.1002/iub.1722 · Cited by 95
Zhao, R., Cai, Z., Li, S., Cheng, Y., Gao, H., Liu, F., Wu, S., Liu, S., Dong, Y., Zheng, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14065 · Cited by 94
Lopes-Rodrigues, V., Luca, A. D., Mleczko, J., Meleady, P., Henry, M. A., Pešić, M., Cabrera, D., Liempd, S. M. V., Lima, R. T., O'Connor, R. A., et al. (2017) · Scientific Reports · doi:10.1038/srep44541 · Cited by 94
Self-citationYANG, G., Wu, D., Zhu, J., Jiang, O., Shi, Q., Tian, J., & Weng, Y. (2013) · Oncology Reports · doi:10.3892/or.2013.2532 · Cited by 93
Wang, T., Ning, K., Lu, T., Sun, X., Jin, L., Qi, X., Jin, J., & Hua, D. (2016) · Cancer Science · doi:10.1111/cas.13150 · Cited by 92
miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1
Lu, F., Zhang, J., JI, M., Li, P., Du, Y., Wang, H., ZANG, S., Ma, D., Sun, X., & Ji, C. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2390 · Cited by 91
Sui, H. X., Cai, G.-X., Pan, S.-F., Deng, W.-L., Wang, Y., Chen, Z., Cai, S.-J., Zhu, H.-R., & Li, Q. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0167 · Cited by 89
Spugnini, E. P., Buglioni, S., Carocci, F., Menicagli, F., Vincenzi, B., Fanciulli, M., & Fais, S. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0225-y · Cited by 88
Acidosis and proteolysis in the tumor microenvironment
Ji, K., Mayernik, L., Moin, K., & Sloane, B. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09796-3 · Cited by 88
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
Spugnini, E. P., Baldi, A., Buglioni, S., Carocci, F., de Bazzichini, G. M., Betti, G., Pantaleo, I., Menicagli, F., Citro, G., & Fais, S. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-221 · Cited by 87
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16 887 Breast Cancer Survivors
Haque, R., Shi, J. M., Schottinger, J. E., Ahmed, S. A., Cheetham, T. C., Chung, J., Avila, C. C., KLEINMAN, K. P., Habel, L. A., Fletcher, S. W., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv337 · Cited by 87
The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer
Shang, Y., Feng, B., Zhou, L., Ren, G., Zhang, Z., Fan, X., Sun, Y., Luo, G., Liang, J., Wu, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6374 · Cited by 86
Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
Hur, J. Y., Kim, H. J., Lee, J. S., Choi, C., Lee, J. C., Jung, M. K., Pack, C., & Lee, K. Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0772-6 · Cited by 86
Goler-Baron, V., Sladkevich, I., & Assaraf, Y. G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.033 · Cited by 83
Self-citationZhang, H., Xie, C., Yue, J., Jiang, Z., Zhou, R., Xie, R., Wang, Y., & Wu, S. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22581 · Cited by 83
Expression and Clinical Significance of the Autophagy Proteins BECLIN 1 and LC3 in Ovarian Cancer
Valente, G., Morani, F., Nicotra, G., Fusco, N., Peracchio, C., Titone, R., Alabiso, O., Arisio, R., Katsaros, D., Benedetto, C., et al. (2014) · BioMed Research International · doi:10.1155/2014/462658 · Cited by 82
Lane, D. A., Matte, I., Garde‐Granger, P., Laplante, C., Carignan, A., Rancourt, C., & Piché, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1511-7 · Cited by 80
ABCC3 as a marker for multidrug resistance in non-small cell lung cancer
Zhao, Y., Lu, H., An, Y., Yang, Y., Meng, Q., Sun, L., Pang, H., Li, C., Dong, X., & Cai, L. (2013) · Scientific Reports · doi:10.1038/srep03120 · Cited by 80
Sung, P., Jan, Y., Lin, S., Huang, C.-C., Lin, H., Wen, K., Chao, K.-C., Lai, C., Wang, P., Chuang, C.-M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6700 · Cited by 80
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer
Dwivedi, S. K. D., Mustafi, S. B., Mangala, L. S., Jiang, D., Pradeep, S., Rodriguez‐Aguayo, C., Ling, H. Y., Ivan, C., Mukherjee, P., Călin, G. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7618 · Cited by 79
Tsoumas, D., Nikou, S., Giannopoulou, E., Tsaniras, S. C., Sirinian, C., Maroulis, I. C., Taraviras, S. L., Zolota, V., Kalofonos, H. P., & Bravou, V. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20071 · Cited by 79
Namløs, H. M., Boye, K., Mishkin, S. J., Barøy, T., Lorenz, S., Bjerkehagen, B., Stratford, E. W., Munthe, E., Kudlow, B. A., Myklebost, O., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0174 · Cited by 79
Zhu, X., Shan, L., Wang, F., Wang, J., Wang, F., Shen, G., Liu, X., Wang, B., Yuan, Y., Ying, J., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3338-y · Cited by 78
Assaraf, Y. G., & SCHIMKE, R. T. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7154 · Cited by 77
Self-citationShargh, S. A., Sakızlı, M., Khalaj, V., Movafagh, A., Yazdi, H., Hagigatjou, E., Sayad, A., Mansouri, N., Mortazavi‐Tabatabaei, S. A., & Khorshid, H. R. K. (2014) · Medical Oncology · doi:10.1007/s12032-014-0250-y · Cited by 77
Overcoming Drug Resistance in Patients with Metastatic Breast Cancer
Wong, S. T.-L., & Goodin, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.8.954 · Cited by 77
Ramos-Esquivel, A., Víquez-Jaikel, Á., & Fernández, C. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.020859 · Cited by 77
Regulatory players of DNA damage repair mechanisms: Role in Cancer Chemoresistance
Sakthivel, K. M., & Hariharan, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.035 · Cited by 77
Busby, J., Mills, K., Zhang, S., Liberante, F. G., & Cardwell, C. R. (2018) · Breast Cancer Research · doi:10.1186/s13058-017-0928-0 · Cited by 77
Gong, J., Luk, F., Jaiswal, R., George, A. M., Grau, G. E., & Bebawy, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.044 · Cited by 76
Assaraf, Y. G., Rothem, L., Hooijberg, J. H., Stark, M., Ifergan, I., Kathmann, I., Dijkmans, B. A. C., Peters, G. J., & Jansen, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209186200 · Cited by 76
Self-citationShalapour, S., Hof, J., Kirschner‐Schwabe, R., Bastian, L., Eckert, C., Prada, J., Henze, G., von Stackelberg, A., & Seeger, K. (2011) · Haematologica · doi:10.3324/haematol.2011.047993 · Cited by 76
Oguri, T., Ozasa, H., Uemura, T., Bessho, Y., Miyazaki, M., Maeno, K., 前田, 浩., Sato, S., & Ueda, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2088 · Cited by 76
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives
Schiffmann, I., Greve, G., Jung, M., & Lübbert, M. (2016) · Epigenetics · doi:10.1080/15592294.2016.1237345 · Cited by 76
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
Madariaga, A., Lheureux, S., & Oza, A. M. (2019) · Cancers · doi:10.3390/cancers11030416 · Cited by 75
Hofbauer, S. L., Stangl, K., de Martino, M., Lucca, I., Haitel, A., Shariat, S. F., & Klatte, T. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.450 · Cited by 74
Hsia, T.-C., Lin, C., Wang, J. J., Ho, S., & Kao, A. (2002) · Lung · doi:10.1007/s004080000091 · Cited by 74
miR‐7 modulates chemoresistance of small cell lung cancer by repressing MRP 1/ ABCC 1
Liu, H., Wu, X., Huang, J., Peng, J., & Guo, L. (2015) · International Journal of Experimental Pathology · doi:10.1111/iep.12131 · Cited by 74
The relationship between platinum drug resistance and epithelial–mesenchymal transition
Brozović, A. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1912-7 · Cited by 74
Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer
Zhang, L., Yao, J., Li, W., & Zhang, C. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14934840662335 · Cited by 74
Mechanisms of Drug Resistance in Cancer: The Role of Extracellular Vesicles
Samuel, P., Fabbri, M., & Carter, D. R. F. (2017) · PROTEOMICS · doi:10.1002/pmic.201600375 · Cited by 74
Rothem, L., Ifergan, I., Kaufman, Y., Priest, D. G., Jansen, G., & Assaraf, Y. G. (2002) · Biochemical Journal · doi:10.1042/bj20020801 · Cited by 73
Self-citationNejo, T., Matsushita, H., Karasaki, T., Nomura, M., Saito, K., Tanaka, S., Takayanagi, S., Hana, T., Takahashi, S., Kitagawa, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0599 · Cited by 73
miR-181b promotes chemoresistance in breast cancer by regulating Bim expression
Zheng, Y., Lv, X., Wang, X., Wang, B., Shao, X., Huang, Y., Shi, L., Chen, Z., Huang, J., & Huang, P. C. (2015) · Oncology Reports · doi:10.3892/or.2015.4417 · Cited by 72
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance
Danza, K., Silvestris, N., Simone, G., Signorile, M., Saragoni, L., Brunetti, O., Monti, M., Mazzotta, A., Summa, S. D., Mangia, A., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139244 · Cited by 72
van Geelen, C. M. M., Westra, J. L., de Vries, E. G. E., Ek, W. B., Zwart, N., Hollema, H., Boezen, H. M., Mulder, N. H., Plukker, J. T. M., de Jong, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8809 · Cited by 71
Muralidharan-Chari, V., Kohan, H. G., Asimakopoulos, A. G., Sudha, T., Sell, S., Kannan, K., Boroujerdi, M., Davis, P. J., & Mousa, S. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10395 · Cited by 71
Rose, S. M. S., Eslinger, J. G., Zimmerman, L., Scaccia, J., Lai, B. S., Lewis, C., & Alisic, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157726 · Cited by 70
Schneider, B. J., Shah, M. A., Klute, K. A., Ocean, A. J., Popa, E., Altorki, N. K., Lieberman, M., Schreiner, A. M., Yantiss, R. K., Christos, P. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1896 · Cited by 70
Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R., & Giles, F. J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0597 · Cited by 70
Atay, S., Wilkey, D. W., Milhem, M. M., Merchant, M. L., & Godwin, A. K. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000267 · Cited by 69
Song, L., Li, Y., Li, W., Wu, S., & Li, Z. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24665 · Cited by 68
Lee, Y., Lee, G. K., Lee, Y., Zhang, W., Hwang, J., Nam, B., Kim, S. H., Joo‐Hang, K. I. M., Yun, T., Han, J., et al. (2014) · Cancer · doi:10.1002/cncr.28711 · Cited by 68
Pal, S. K., Miller, M. J., Agarwal, N., Chang, S. M., Chávez‐MacGregor, M., Cohen, E. E. W., Cole, S., Dale, W., Diefenbach, C., Disis, M. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02037 · Cited by 68
Schroth, W., Winter, S., Mürdter, T. E., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00582 · Cited by 67
Hilton, J. F., Tu, D., Seymour, L., Shepherd, F. A., & Bradbury, P. A. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.008 · Cited by 65
ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer
Oguri (1994) · Oncology Reports · doi:10.3892/or_00000217 · Cited by 65
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Ball, B. J., Zeidan, A. M., Gore, S. D., & Prébet, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228927 · Cited by 65
Martinelli, C. M. D. S., Lengert, A. V. H., Cárcano, F. M., da Silva, E. C. A., Brait, M., Lopes, L. F., & Vidal, D. O. (2016) · Oncotarget · doi:10.18632/oncotarget.11167 · Cited by 64
de Klerk, D. J., Honeywell, R. J., Jansen, G., & Peters, G. J. (2018) · Cancers · doi:10.3390/cancers10120503 · Cited by 64
Bewersdorf, J. P., & Zeidan, A. M. (2019) · Leukemia · doi:10.1038/s41375-019-0448-2 · Cited by 64
Potential of epigenetic therapies in the management of solid tumors
Valdespino, V., & Valdespino-Castillo, P. M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s70358 · Cited by 63
Breast cancer recurrence risk in relation to antidepressant use after diagnosis
Chubak, J., Buist, D. S. M., Boudreau, D. M., Rossing, M. A., Lumley, T., & Weiss, N. S. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9828-9 · Cited by 63
Wang, Y., Zhang, Y., Kathawala, R. J., & Chen, Z. (2014) · Cancers · doi:10.3390/cancers6041925 · Cited by 63
Shuhua, W., Sun, C., Yangyang, L., Xiangqian, G., He, S., Li, T., & Dong, T. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.07.016 · Cited by 62
Zhan, M., Zhao, X., Wang, H., Chen, W., Xu, S., Wang, W., Shen, H., Huang, S., & Wang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4957-6 · Cited by 62
Targeting of epigenetic regulators in neuroblastoma
Jubierre, L., Jiménez, C., Rovira, E., Soriano, A., Sábado, C., Gros, L., Llort, A., Hladun, R., Roma, J. M., de Toledo, J. S., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0077-2 · Cited by 62
Therapy‐induced enrichment of putative lung cancer stem‐like cells
Freitas, D. P., Teixeira, C. A., Santos‐Silva, F., Vasconcelos, M. H., & Almeida, G. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28478 · Cited by 61
Self-citationSun, J., Ilich, A., Kim, C., Chu, M. P., Wong, G. G., Ghosh, S., Danilak, M., Mulder, K. E., Spratlin, J. L., Chambers, C. R., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.12.008 · Cited by 60
Hollis, R. L., Churchman, M., & Gourley, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s102569 · Cited by 60
Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia
Ferrao, P., Sincock, P. M., Cole, S. R., & Ashman, L. K. (2001) · Leukemia Research · doi:10.1016/s0145-2126(00)00156-9 · Cited by 59
Zhang, Y., Zhou, S., Yan, H., Xu, D., Chen, H.-X., Wang, X., Wang, X., Liu, Y., Zhang, L., Wang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep19995 · Cited by 59
OCT1 and imatinib transport in CML: is it clinically relevant?
Watkins, D. B., Hughes, T. P., & White, D. L. (2015) · Leukemia · doi:10.1038/leu.2015.170 · Cited by 58
OVEREXPRESSION OF XIAP EXPRESSION IN RENAL CELL CARCINOMA PREDICTS WORSE PROGNOSIS
Mizutani, Y., Nakanishi, H., Shiraishi, T., Nakamura, T., Mikami, K., Takaha, N., Okihara, K., Ukimura, O., Kawauchi, A., & Miki, T. (2008) · The Journal of Urology · doi:10.1016/s0022-5347(08)60387-0 · Cited by 58
Malofeeva, E. V., Domanitskaya, N., Gudima, M., & Hopper-Borge, E. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1340 · Cited by 58
Xiong, Y., Huang, B., & Yin, J. (2017) · Medical Oncology · doi:10.1007/s12032-017-0905-6 · Cited by 58
Regulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axis
Cao, W., Wei, W., Zhan, Z., Xie, D., Xie, Y., & Xiao, Q. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3381 · Cited by 58
User considerations in assessing pharmacogenomic tests and their clinical support tools
Mukerjee, G., Huston, A., Kabakchiev, B., Piquette‐Miller, M., van Schaik, R. H., & Dorfman, R. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0065-4 · Cited by 58
Matulonis, U. A., Berlin, S. T., Lee, H., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2813-9 · Cited by 57
Benson, E. A., Skaar, T. C., Liu, Y., Nephew, K. P., & Matei, D. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141279 · Cited by 57
The potential of exosomes derived from colorectal cancer as a biomarker
Xiao, Y., Li, Y., Yuan, Y., Liu, B., Pan, S., Liu, Q., Qi, X., Zhou, H., Dong, W., & Li, J. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.007 · Cited by 57
Wang, R., Li, Y., Hou, Y., Yang, Q., Chen, S., Wang, X., Wang, Z., Yang, Y. F., Chen, C., Wang, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3193 · Cited by 56
Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer
Al-Bazz, Y. O., Underwood, J. C. E., BROWN, B. L., & Dobson, P. R. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.044 · Cited by 56
Lee, Y.-Y., Jeon, H., Hong, J. E., Cho, Y., Ryu, J., Choi, J., Lee, S. H., Yoon, G., Kim, W. Y., Do, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5319 · Cited by 56
MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.
Tian, J., Xu, Y., Li, L., & Hao, Q. (2017) · PubMed Central · Cited by 56
Lu, T., Chen, D., Wang, Y., Sun, X., Li, S., Miao, S., Wo, Y., Dong, Y., Leng, X., Du, W., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0770-9 · Cited by 56
Li, F., Xu, Y., Deng, S., Li, Z., Zou, D., Yi, S., Sui, W., Hao, M., & Qiu, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5681 · Cited by 55
Curry, E. W., Zeller, C., Masrour, N., Patten, D. K., Gallon, J., Wilhelm-Benartzi, C. S., Ghaem‐Maghami, S., Bowtell, D. D. L., & Brown, R. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1650 · Cited by 55
Staudigl, C., Concin, N., Grimm, C., Pfeiler, G., Nehoda, R., Singer, C. F., & Polterauer, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125317 · Cited by 54
Zhou, S., Huang, Q., Zheng, S., Lin, K., You, J., & Zhang, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-4500-1 · Cited by 54
Zhao, L., Li, Y., Song, X., Zhou, H., Li, N., Miao, Y., & Li, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11054 · Cited by 54
Wu, Z., Yang, Z., Li, C. S., Zhao, W. M., Liang, Z. X., Dai, Y., Zhu, Q., Miao, K. L., Cui, D. H., & Chen, L. A. (2019) · Cancer Medicine · doi:10.1002/cam4.1935 · Cited by 54
de Carvalho, F., Colleoni, G. W. B., Almeida, M. S. S., Carvalho, A. L., & Vettore, A. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24431 · Cited by 53
Bártková, J., Meyts, E. R., Skakkebæk, N. E., Lukáš, J., & Bártek, J. (2007) · International Journal of Andrology · doi:10.1111/j.1365-2605.2007.00772.x · Cited by 53
Kawasaki, M., Nakanishi, Y., Kuwano, K., Takayama, K., Kiyohara, C., & Hara, N. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00067-7 · Cited by 53
Hu, S., Niu, H., Inaba, H., Orwick, S. J., Rose, C., Panetta, J. C., Yang, S., Pounds, S. B., Fan, Y., Calabrese, C. R., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr107 · Cited by 53
Giovannetti, E., Pacetti, P., Reni, M., León, L. G., Mambrini, A., Vasile, E., Ghidini, M., Funel, N., Lucchesi, M., Cereda, S., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.109 · Cited by 53
Donneyong, M. M., Bykov, K., Bosco‐Lévy, P., Dong, Y., Levin, R., & Gagne, J. J. (2016) · BMJ · doi:10.1136/bmj.i5014 · Cited by 53
Sieger, P., Cui, Y., & Scheuerer, S. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.04.016 · Cited by 53
DNA Methylation Profiling as a Tool for Testicular Germ Cell Tumors Subtyping
Costa, A. L., Moreira-Barbosa, C., Lobo, J., Vilela-Salgueiro, B., Cantante, M., Guimarães, R., Lopes, P., Braga, I. C., Oliveira, J., Antunes, L., et al. (2018) · Epigenomics · doi:10.2217/epi-2018-0034 · Cited by 52
Cited by
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Self-citationAnticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Self-citationApoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Metadata
- Authors
- Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 46
- Pages
- 100645
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2974459221
- Cited by
- 528
- References
- 482
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.